Health Care [ 11/12 ] | Pharmaceuticals [ 49/75 ]
NASDAQ | Common Stock
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.
The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown.
It also provides dermal filler products under the Estyme and Evolysse names.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 24 | -0.04 Increased by +78.95% | -0.05 Increased by +20.00% |
| May 7, 24 | -0.09 Increased by +40.00% | -0.10 Increased by +10.00% |
| Mar 7, 24 | -0.12 Increased by +14.29% | -0.07 Decreased by -71.43% |
| Nov 7, 23 | -0.16 Increased by +42.86% | -0.17 Increased by +5.88% |
| Aug 2, 23 | -0.19 Increased by +32.14% | -0.19 |
| May 9, 23 | -0.15 Increased by +31.82% | -0.15 |
| Mar 8, 23 | -0.14 Increased by +36.36% | -0.15 Increased by +6.67% |
| Nov 8, 22 | -0.28 Decreased by -3.70% | -0.28 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 59.33 M Increased by +42.21% | -13.11 M Increased by +11.37% | Decreased by -22.09% Increased by +37.68% |
| Dec 31, 23 | 61.00 M Increased by +39.76% | -11.83 M Increased by +10.13% | Decreased by -19.40% Increased by +35.69% |
| Sep 30, 23 | 49.32 M Increased by +45.50% | -16.92 M Increased by +16.54% | Decreased by -34.31% Increased by +42.64% |
| Jun 30, 23 | 49.35 M Increased by +32.78% | -18.14 M Increased by +22.71% | Decreased by -36.76% Increased by +41.79% |
| Mar 31, 23 | 41.72 M Increased by +23.04% | -14.79 M Increased by +15.48% | Decreased by -35.45% Increased by +31.31% |
| Dec 31, 22 | 43.65 M Increased by +25.94% | -13.16 M Increased by +27.58% | Decreased by -30.16% Increased by +42.49% |
| Sep 30, 22 | 33.90 M Increased by +27.07% | -20.28 M Decreased by -4.34% | Decreased by -59.81% Increased by +17.89% |
| Jun 30, 22 | 37.16 M Increased by +42.40% | -23.47 M Decreased by -50.45% | Decreased by -63.16% Decreased by -5.65% |